Safety and Performance of Motiva® Sizers
Post-marketing Cohort Study to Confirm the Safety and Performance of Motiva® Sizers in Breast Augmentation and Reconstruction Procedures
1 other identifier
observational
330
1 country
1
Brief Summary
The Motiva® Sizer clinical study is a four-year, multicenter, post-marketing, and cohort study, designed to confirm the safety and performance of Motiva® Sizer in breast augmentation or reconstruction procedures. The research will include 330 women, divided into two groups of 165 participants each (150 breast augmentation participants and 15 reconstruction participants). The Motiva® Sizer exposed group will consist of women who will undergo breast augmentation or reconstruction surgery with the use of Motiva® Sizer during the procedure, and a non-exposed group will consist of women who will undergo breast augmentation or reconstruction surgery without the use of Motiva® Sizer. This study will be conducted in Costa Rica. The main goal is to evaluate the safety and the performance of the Motiva® Sizer. To this end, the results of both groups will be compared in terms of surgical complications, surgeon's, and participant's satisfaction level as well as reoperation rates. After the augmentation or reconstruction surgery, participants will be scheduled for the following follow-up visits, (1) between 3 and 7 postoperative days, (2) between 3 and 6 postoperative weeks, (3) at 3 and (4) 6 postoperative months, and (5, 6 and 7) annually thereafter for a period of three consecutive years. In case any participant has an adverse event due to the procedure, and if required by the physician, an additional visit will be made to assess her, and this information as well as that of the scheduled visits should be recorded in the electronic data collection notebook.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 10, 2023
CompletedFirst Submitted
Initial submission to the registry
December 27, 2023
CompletedFirst Posted
Study publicly available on registry
February 23, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 10, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 10, 2027
February 23, 2024
February 1, 2024
4 years
December 27, 2023
February 15, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Motiva Sizers Safety (complications)
Cumulative incidence of complications between participants in whom Motiva® Sizer was used during breast augmentation or reconstruction surgery, and participants in whom intraoperative breast sizers were not used during breast augmentation or reconstruction surgery
3 years
Motiva Sizers Performance (satisfaction)
Percentage of participants and surgeons who are satisfied or very satisfied with surgery´s results with and without Motiva® Sizer. (based on 5-point Likert scale, in which 1 is Very dissatisfied, 2 Dissatisfied, 3 Neither satisfied nor dissatisfied, 4 Satisfied, 5 Very satisfied) measured at 3rd, 6th months after surgery and 1st, 2nd and 3rd year.
3 years
Secondary Outcomes (1)
Motiva Sizers Safety (reoperations)
3 years
Study Arms (2)
Women who will undergo a breast augmentation or reconstruction with Motiva® Sizer during surgery.
Women who will undergo a breast augmentation or reconstruction without Motiva® Sizer during surgery.
Interventions
No intervention will be made,
Eligibility Criteria
Women over 18 years of age who will undergo breast augmentation or reconstruction. They will be divided into two groups: * Group exposed to Motiva® Sizer: 165 participants (150 breast augmentation participants and 15 reconstruction participants). * Group not exposed to Motiva® Sizer: 165 participants (150 breast augmentation participants and 15 reconstruction participants).
You may qualify if:
- Female, 18 years of age or older.
- The participant will be undergoing a breast augmentation or reconstruction procedure.
- To possess enough and adequate tissue to cover the implants.
- Willingness to comply with all study requirements, including signing the informed consent document and agreeing to attend all required follow-up visits.
You may not qualify if:
- Existing rib injuries.
- Inadequate or unsuitable tissue for augmentation or reconstruction surgery at the physician's discretion.
- History of abscesses or infections in the breast area.
- Current pregnancy or breastfeeding, or full-term pregnancy or breastfeeding in the six months prior to enrollment.
- History of sensitivity to silicone.
- Any medical condition, such as underweight or obesity, diabetes, autoimmune disease or severe chronic pulmonary or cardiovascular disease, psychological/psychiatric disorders that may result in unduly high surgical risk and/or significant postoperative complications.
- Active or recurrent breast cancer.
- Consumption of any medication that, in the investigator's experience, may pose an increased risk of complications or interfere with wound healing ability, such as corticosteroid therapy or blood clotting medication (e.g., concomitant treatment with warfarin).
- Not living in the country where the procedure was performed , which prevents him/her from attending follow-up visits .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Establishment Labs
Coyol, Alajuela Province, 20102, Costa Rica
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 27, 2023
First Posted
February 23, 2024
Study Start
April 10, 2023
Primary Completion (Estimated)
April 10, 2027
Study Completion (Estimated)
July 10, 2027
Last Updated
February 23, 2024
Record last verified: 2024-02